{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:57:23Z","timestamp":1793041043274,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.esmoop.2026.107698","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T21:28:31Z","timestamp":1779830911000},"page":"107698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8794-130X","authenticated-orcid":false,"given":"S.B.","family":"Maron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-8534","authenticated-orcid":false,"given":"R.-H.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.A.","family":"Wainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Y.","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.S.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3187-7393","authenticated-orcid":false,"given":"M.-H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5739-0175","authenticated-orcid":false,"given":"K.","family":"Korphaisarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Elimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Calderon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6385-7288","authenticated-orcid":false,"given":"F.V.","family":"Herpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.P.","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1453-3548","authenticated-orcid":false,"given":"M.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Isse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"Yanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"K.","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2026.107698_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107698_bib3","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.107698_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.2296","article-title":"LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer (GC\/GEJC)\/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study","volume":"31","author":"Moehler","year":"2020","journal-title":"Ann Oncol"},{"issue":"10251","key":"10.1016\/j.esmoop.2026.107698_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107698_bib6","first-page":"Cd004064","article-title":"Chemotherapy for advanced gastric cancer","volume":"8","author":"Wagner","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"10.1016\/j.esmoop.2026.107698_bib7","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.3390\/jcm12144646","article-title":"Novel biomarkers of gastric cancer: current research and future perspectives","volume":"12","author":"Sato","year":"2023","journal-title":"J Clin Med"},{"issue":"10418","key":"10.1016\/j.esmoop.2026.107698_bib8","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"issue":"10294","key":"10.1016\/j.esmoop.2026.107698_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107698_bib10","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107698_bib11","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"10389","key":"10.1016\/j.esmoop.2026.107698_bib12","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.107698_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107698_bib14","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107698_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1981202","article-title":"Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer","volume":"13","author":"Xiang","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.esmoop.2026.107698_bib16","article-title":"Prevalence of FGFR2b protein overexpression in advanced gastric cancers during prescreening for the phase III FORTITUDE-101 trial","volume":"9","author":"Rha","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107698_bib17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","article-title":"Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial","volume":"27","author":"Wainberg","year":"2024","journal-title":"Gastric Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2026.107698_bib18","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/modpathol.2016.96","article-title":"FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival","volume":"29","author":"Ahn","year":"2016","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107698_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000441149","article-title":"Evaluation of fibroblast growth factor receptor 2 expression, heterogeneity and clinical significance in gastric cancer","volume":"82","author":"Han","year":"2015","journal-title":"Pathobiology"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107698_bib20","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1038\/s41598-021-84107-x","article-title":"Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer","volume":"11","author":"Yashiro","year":"2021","journal-title":"Sci Rep"},{"issue":"Suppl 19","key":"10.1016\/j.esmoop.2026.107698_bib21","article-title":"Abstract 5446: FPA144: a therapeutic antibody for treating patients with gastric cancers bearing FGFR2 gene amplification","volume":"74","author":"Gemo","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2026.107698_bib22","article-title":"Genomic landscape of late-stage gastric cancer: analysis from KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 studies","volume":"9","author":"Janjigian","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107698_bib23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12957-017-1132-5","article-title":"The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature","volume":"15","author":"Lei","year":"2017","journal-title":"World J Surg Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107698_bib24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s10120-024-01578-3","article-title":"Comprehensive histopathological analysis of gastric cancer in European and Latin American populations reveals differences in PDL1, HER2, p53 and MUC6 expression","volume":"28","author":"Mart\u00ednez-Ciarpaglini","year":"2025","journal-title":"Gastric Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107698_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znaf280","article-title":"Genomic and clinical parallels between US and Japanese gastric cancers: a propensity score-matched cohort study","volume":"112","author":"Nakauchi","year":"2025","journal-title":"Br J Surg"},{"issue":"7903","key":"10.1016\/j.esmoop.2026.107698_bib26","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107698_bib27","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1245\/s10434-011-1695-2","article-title":"Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1414 cases of whole-tissue sections and 595 cases of tissue microarrays","volume":"18","author":"Kim","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107698_bib28","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/modpathol.2012.205","article-title":"Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas","volume":"26","author":"Cho","year":"2013","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107698_bib29","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s10620-005-9057-1","article-title":"HER-2\/neu amplification is an independent prognostic factor in gastric cancer","volume":"51","author":"Park","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.esmoop.2026.107698_bib30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1746-1596-8-76","article-title":"HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population","volume":"8","author":"Shan","year":"2013","journal-title":"Diagn Pathol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107698_bib31","first-page":"65","article-title":"Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer","volume":"15","author":"Yano","year":"2006","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107698_bib32","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/1078-0432.CCR-11-2272","article-title":"Association of HER2\/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas","volume":"18","author":"Yoon","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107698_bib33","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10120-021-01195-4","article-title":"Optimized PD-L1 scoring of gastric cancer","volume":"24","author":"Schoemig-Markiefka","year":"2021","journal-title":"Gastric Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107698_bib34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107698_bib35","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107698_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100778","article-title":"Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas","volume":"8","author":"Klempner","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.107698_bib37","doi-asserted-by":"crossref","first-page":"S885","DOI":"10.1016\/j.annonc.2024.08.1486","article-title":"1420P Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression and biomarker overlap in patients with advanced gastric or gastroesophageal junction cancer (GC\/GEJC)","volume":"35","author":"Sato","year":"2024","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:24:31Z","timestamp":1783052671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926016406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2059702926016406"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107698","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107698"}}